Cagrilintide

Cagrilintide is a long-acting amylin analogue studied in metabolic and appetite-regulation research. Amylin is a peptide hormone co-secreted with insulin by pancreatic beta cells and is involved in satiety signaling, gastric-emptying regulation, glucagon modulation, and energy-balance pathways. Cagrilintide was developed to mimic selected amylin-like effects while extending activity compared with native amylin.

Cagrilintide research has focused heavily on weight-management biology, appetite pathways, and combination research with GLP-1 receptor agonists such as semaglutide. A 2024 review describes cagrilintide as an amylin analogue being developed in combination with semaglutide for sustained weight-loss research, noting that amylin exerts satiety-related effects through both homeostatic and hedonic brain regions.

Specifications

Molecular Formula: C194H312N54O59S2
Molecular Weight: approximately 4109–4110 g/mol
Primary Research Target: Amylin receptor pathways
Compound Class: Long-acting amylin analogue peptide

Cagrilintide Research

Cagrilintide and Amylin Receptor Research

Cagrilintide is studied as an amylin analogue, meaning it is designed to interact with amylin-related receptor pathways. Amylin signaling is involved in meal-size regulation, satiety, gastric emptying, and energy-balance research. These pathways overlap with, but remain distinct from, GLP-1 receptor signaling.

Cagrilintide and Appetite-Signaling Research

Amylin-related compounds are of interest because they appear to influence both homeostatic appetite circuits and reward-related feeding pathways. This makes cagrilintide relevant to studies investigating food intake, satiety duration, body-weight regulation, and neuroendocrine control of appetite.

Cagrilintide and Combination Research

Cagrilintide has been studied both alone and in combination with semaglutide. A phase 2 trial reported that once-weekly cagrilintide exposure was associated with significant body-weight reductions and was generally well tolerated in the studied population. More recently, REDEFINE-1 reported that cagrilintide–semaglutide produced significant and clinically relevant body-weight reductions compared with placebo in adults with overweight or obesity.

References

D’Ascanio AM, et al. A long-acting amylin analog for the treatment of obesity. J Clin Endocrinol Metab. 2024.

Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity. Lancet. 2021.

Dehestani B, et al. Amylin as a future obesity treatment. J Clin Med. 2021.

Coadministered cagrilintide and semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2025.

Disclaimer: This product is not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited. All information shared here is for educational and research-reference purposes only.